论文部分内容阅读
高血压病及其相关的心血管疾病已成为导致死亡的首要原因之一;但全球药物降压达标率仍较低,其原因之一与个体间药物疗效差异较大相关,而药物的个体反应差异又很大程度与遗传背景有关。过去的10多年来,探讨高血压药物基因组学研究,以及寻找降压疗效相关基因方面进行了大量研究并取得成果;特别是部分β受体阻滞剂、钙离子拮抗剂,血管紧张素转换酶抑制剂的疗效差异与相关药物的代谢酶、受体的基因多态性明显相关,部分小样本研究结果显示可应用于个体间药物降压疗效差异的预测;然而大部分研究结果又显示单纯根据药物基因组学预测药物降压疗效差异仍然存在诸多的挑战。
Hypertension and its related cardiovascular diseases have become one of the leading causes of death. However, the global compliance rate of drug antihypertensive is still low, one of the reasons is related to the large difference in drug efficacy between individuals. The individual response The difference is largely related to the genetic background. Over the past 10 years, there has been a great deal of research and results on the research of hypertension drug genomics and looking for genes related to antihypertensive effect. In particular, partial beta blockers, calcium antagonists, angiotensin converting enzyme The difference of the curative effect of inhibitors is related to the genetic polymorphisms of metabolic enzymes and receptors of related drugs. Some small sample results show that they can be used in the prediction of the difference of antihypertensive effects between individuals. However, most of the results show that the simple basis Pharmacogenomics predict drug antihypertensive efficacy differences still have many challenges.